Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products.

Zaman SM, Hill FG, Palmer B, Millar CM, Bone A, Molesworth AM, Connor N, Lee CA, Dolan G, Wilde JT, Gill ON, Makris M.

Haemophilia. 2011 Nov;17(6):931-7. doi: 10.1111/j.1365-2516.2011.02508.x. Epub 2011 Feb 23.

PMID:
21342369
2.

A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease.

Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I.

Haemophilia. 2011 Jan;17(1):165-6. doi: 10.1111/j.1365-2516.2010.02381.x. No abstract available.

PMID:
21199188
3.

A novel alanine or threonine 789 to proline mutation causing type 2N von Willebrand's disease when inherited homozygously or heterozygously with arginine 854 to glutamine mutation.

Enayat MS, Guilliatt AM, Short PE, Rastegar-Lari G, Jazebi M, Ravonbod S, Ala F, Chapman OG, Hill FG.

Haemophilia. 2010 Nov;16(6):966-9. doi: 10.1111/j.1365-2516.2010.02271.x. No abstract available.

PMID:
20491956
4.

Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders.

Millar CM, Connor N, Dolan G, Lee CA, Makris M, Wilde J, Winter M, Ironside JW, Gill N, Hill FG.

Haemophilia. 2010 Mar;16(2):305-15. doi: 10.1111/j.1365-2516.2010.02220.x.

PMID:
20487442
5.

Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.

Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW.

Haemophilia. 2010 Mar;16(2):296-304. doi: 10.1111/j.1365-2516.2009.02181.x. Epub 2010 Jan 12.

PMID:
20070383
6.

Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre.

Motwani J, Jesson J, Sturch E, Jones S, Eyre L, Short P, Davies P, Williams MD, Darbyshire PJ, Hill FG, Lawson S.

Br J Haematol. 2009 Jan;144(1):133-5. doi: 10.1111/j.1365-2141.2008.07410.x. Epub 2008 Oct 25. No abstract available.

PMID:
19016737
7.

Unique heterozygous intron 22 inversion band pattern in a haemophilic male detected by long polymerase chain reaction (PCR).

Theophilus BD, Enayat MS, Green PM, Wilde JT, Hill FG.

Thromb Haemost. 2008 Apr;99(4):774-5. doi: 10.1160/TH07-12-0731. No abstract available.

PMID:
18392336
8.

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR.

Blood. 2008 May 15;111(10):4979-85. doi: 10.1182/blood-2007-09-110940. Epub 2008 Mar 14.

9.

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M.

Blood. 2007 Aug 1;110(3):815-25. Epub 2007 Apr 19.

10.
11.

Inherited and de novo von Willebrand disease 'Vicenza' in UK families with the R1205H mutation: diagnostic pitfalls and new insights.

Lester WA, Guilliatt AM, Surdhar GK, Enayat SM, Wilde JT, Willoughby S, Grundy P, Cumming AM, Collins PW, Hill FG.

Br J Haematol. 2006 Oct;135(1):91-6. Epub 2006 Aug 22.

PMID:
16925796
12.

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB; Working Party on von Willebrand Disease Classification.

J Thromb Haemost. 2006 Oct;4(10):2103-14. Epub 2006 Aug 2. Review.

13.

The usefulness of bone marrow aspiration in the diagnosis of Niemann-Pick disease type C in infantile liver disease.

Rodrigues AF, Gray RG, Preece MA, Brown R, Hill FG, Baumann U, McKiernan PJ.

Arch Dis Child. 2006 Oct;91(10):841-4. Epub 2006 May 31.

14.

6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience.

Ravikumara M, Hill FG, Wilson DC, Gillett PM, Thomas A, Brown R, Darbyshire PJ, McKiernan PJ.

J Pediatr Gastroenterol Nutr. 2006 May;42(5):535-8.

PMID:
16707977
15.

Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance.

Enayat MS, Guilliatt AM, Lester W, Wilde JT, Williams MD, Hill FG.

Br J Haematol. 2006 Jun;133(6):664-6.

PMID:
16704444
16.

Management of neonates with inherited bleeding disorders--a survey of current UK practice.

Chalmers EA, Williams MD, Richards M, Brown SA, Liesner R, Thomas A, Vidler V, Pasi KJ, Hill FG; Paediatric Working Party of Ukhcdo.

Haemophilia. 2005 Mar;11(2):186-7. No abstract available.

PMID:
15810924
17.

A framework for genetic service provision for haemophilia and other inherited bleeding disorders.

Ludlam CA, Pasi KJ, Bolton-Maggs P, Collins PW, Cumming AM, Dolan G, Fryer A, Harrington C, Hill FG, Peake IR, Perry DJ, Skirton H, Smith M; UK Haemophilia Centre Doctors' Organisation.

Haemophilia. 2005 Mar;11(2):145-63.

PMID:
15810917
18.

The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype.

Bowen DJ, Collins PW, Lester W, Cumming AM, Keeney S, Grundy P, Enayat SM, Bolton-Maggs PH, Keeling DM, Khair K, Tait RC, Wilde JT, Pasi KJ, Hill FG; UK Haemophilia Centre Doctors' Organization.

Br J Haematol. 2005 Mar;128(6):830-6.

PMID:
15755288
19.

Mutation analysis in F9 gene of 17 families with haemophilia B from Iran.

Enayat MS, Karimi M, Chana G, Farjadian S, Theophilus BD, Hill FG.

Haemophilia. 2004 Nov;10(6):751-5.

PMID:
15569175
20.

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, Hill FG, Hay CR; UK Haemophilia Centre Doctors' Organisation.

J Thromb Haemost. 2004 Jul;2(7):1047-54.

21.

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia.

Harrison CJ, Moorman AV, Broadfield ZJ, Cheung KL, Harris RL, Reza Jalali G, Robinson HM, Barber KE, Richards SM, Mitchell CD, Eden TO, Hann IM, Hill FG, Kinsey SE, Gibson BE, Lilleyman J, Vora A, Goldstone AH, Franklin IM, Durrant J, Martineau M; Childhood and Adult Leukaemia Working Parties.

Br J Haematol. 2004 Jun;125(5):552-9.

PMID:
15147369
22.

Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.

Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, Hay CR, Hill FG, Laffan M, Peake IR.

Haemophilia. 2004 May;10(3):218-31.

PMID:
15086319
23.

The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.

Laffan M, Brown SA, Collins PW, Cumming AM, Hill FG, Keeling D, Peake IR, Pasi KJ.

Haemophilia. 2004 May;10(3):199-217.

PMID:
15086318
24.

Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).

Hill FG, Richards S, Gibson B, Hann I, Lilleyman J, Kinsey S, Mitchell C, Harrison CJ, Eden OB; UK Medical Research Council Working Party on Childhood Leukaemia.

Br J Haematol. 2004 Jan;124(1):33-46.

PMID:
14675406
25.

Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia.

Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR, Broadfield ZJ, Harris RL, Taylor KE, Gibson BE, Hann IM, Hill FG, Kinsey SE, Eden TO, Mitchell CD, Harrison CJ; United Kingdom Medical Research Council's Childhood Leukemia Working Party.

Blood. 2003 Oct 15;102(8):2756-62. Epub 2003 Jun 26.

26.

Intraocular relapse of childhood acute lymphoblastic leukaemia.

Somervaille TC, Hann IM, Harrison G, Eden TO, Gibson BE, Hill FG, Mitchell C, Kinsey SE, Vora AJ, Lilleyman JS; MRC Childhood Leukaemia Working Party.

Br J Haematol. 2003 Apr;121(2):280-8.

PMID:
12694250
27.

Third and fourth Workshops of the European Paediatric Network for Haemophilia Management.

Hill FG, Ljung R; European Paediatric Network for Haemophilia Management.

Haemophilia. 2003 Mar;9(2):223-8. No abstract available.

PMID:
12614375
28.

Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia.

Morris EC, Harrison G, Bailey CC, Hann IM, Hill FG, Gibson BE, Richards S, Webb DK; Medical Research Council Childhood Leukaemia Working Party.

Br J Haematol. 2003 Mar;120(5):787-9.

PMID:
12614210
29.

An unrelated cytogenetic karyotype and intra-lineage shift at relapse of an aggressive paediatric B-precursor ALL.

Weston VJ, Stankovic T, McMullan DJ, Drayson M, Ley BE, Lawson S, Hill FG.

Leukemia. 2002 Nov;16(11):2337-9. No abstract available.

30.
31.

Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI.

Chessells JM, Harrison G, Richards SM, Gibson BE, Bailey CC, Hill FG, Hann IM; Medical Research Council Working Party On Childhood Leukaemia.

Br J Haematol. 2002 Aug;118(2):445-55.

PMID:
12139731
32.

Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.

Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE, Hann IM.

Arch Dis Child. 2001 Oct;85(4):321-5.

34.

Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A.

Theophilus BD, Enayat MS, Williams MD, Hill FG.

Haemophilia. 2001 Jul;7(4):381-91.

PMID:
11442643
35.

Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development.

Surdhar GK, Enayat MS, Lawson S, Williams MD, Hill FG.

Blood. 2001 Jul 1;98(1):248-50. No abstract available.

36.

Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM, Hann IM, Hill FG, Gibson BE.

Leukemia. 2000 Dec;14(12):2307-20.

PMID:
11187922
37.

Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI).

Hargrave DR, Hann II, Richards SM, Hill FG, Lilleyman JS, Kinsey S, Bailey CC, Chessells JM, Mitchell C, Eden OB; Medical Research Council Working Party for Childhood Leukaemia.

Br J Haematol. 2001 Feb;112(2):293-9.

PMID:
11167821
38.

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM.

Br J Haematol. 2000 Oct;111(1):78-90. No abstract available.

PMID:
11091185
39.

A new candidate missense mutation (Leu 1657 IIe) in an apparently asymptomatic type 2A (phenotype IIA) von Willebrand disease family.

Enayat MS, Guilliatt AM, Surdhar GK, Theophilus BD, Hill FG.

Thromb Haemost. 2000 Sep;84(3):369-73.

PMID:
11019957
41.
42.

Pediatric oncology and hematology in Birmingham, England.

Mann JR, Darbyshire PJ, Goodman A, Hill FG, Gornall P, Hockley AD, McConville C, Morland BJ, Parkes SE, Raafat F, Ramani P, Spooner D, Stevens MC, Walsh R, Williams MD.

Pediatr Hematol Oncol. 1999 Jan-Feb;16(1):3-7.

PMID:
9932268
44.

Plasma levels of von Willebrand factor antigen in acute bronchitis and in a normal population.

Boldy DA, Short PE, Cowen P, Hill FG, Chambers DC, Ayres JG.

Respir Med. 1998 Mar;92(3):395-400.

45.

Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.

Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E.

Thromb Haemost. 1998 Apr;79(4):762-6.

PMID:
9569189
46.

Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Yao QY, Croom-Carter DS, Tierney RJ, Habeshaw G, Wilde JT, Hill FG, Conlon C, Rickinson AB.

J Virol. 1998 May;72(5):4352-63.

47.

A new (K1518E) candidate mutation detected by universal heteroduplex generator analysis in a patient with type 2A (phenotype IIA) von Willebrand disease.

Enayat MS, Theophilus BD, Hill FG, Rose PE, Culpan D, Bidwell J, Standen GR.

Thromb Haemost. 1998 Jan;79(1):240. No abstract available.

PMID:
9459358
48.

Another variant pattern of intron 22 inversion in the factor VIII gene seen in a severe haemophilia A patient.

Enayat MS, Theophilus BD, Williams MD, Wilde JT, Hill FG.

Thromb Haemost. 1997 Oct;78(4):1303. No abstract available.

PMID:
9365008
49.

Supplemental Content

Support Center